Objective: To determine the effectiveness of glucocorticoid treatment in children with croup.
2
The results suggest that THS was stable following treatment with glucocorticoid therapy.
3
The magnitude of this reduction was similar with treatment of either glucocorticoid.
4
Only men without acute disease exacerbation or systemic glucocorticoid treatment were included.
5
FKBP5 regulates the cortisol-binding affinity and nuclear translocation of the glucocorticoid receptor.
1
Iatrogenic osteoporosis is a very common secondary osteoporosis is found in patients treated with large dosage of glucocorticosteroid of long duration.
2
The efficacy of a glucocorticosteroid-inducible promoter was assessed in controlling transgene expression following lentivirus-mediated gene transfer to ovine and human corneas.
3
The duration of treatment of primary disease with glucocorticosteroid is 1 to 3.5 years, with the average of 1.56 years.
4
At presentation, all patients except one had been inappropriately treated with glucocorticosteroid (insufficiently dosed or tapered too fast) for longer than 2 weeks.
5
The mechanisms appear to involve effects at the cell membrane as well as nuclear actions mediated by intracellular mineralo- and glucocorticosteroid receptors (MR and GR).
1
In the present paper the fluorescence properties of C60-glucocorticoids were firstly investigated.
2
We investigated whether cosyntropin testing predicts treatment response to glucocorticoids in CAP.
3
All of the 5 patients in stage III accepted glucocorticoids after diagnosis.
4
At the same time, the use of glucocorticoids was also very important.
5
The response to traditional therapy such as glucocorticoids may also be compromised.
6
In the absence of infection, glucocorticoids may also be effective in PPHN.
7
Moreover, GR acts in a dose-dependent manner at physiological concentrations of glucocorticoids.
8
The primary anti-inflammatory mechanism of glucocorticoids is thought to be NF-kappaB inhibition.
9
Interleukin-17A participates centrally in stages of the inflammatory response and glucocorticoids insensitivity.
10
Treating the resistant cells with a MEK inhibitor sensitized them to glucocorticoids.
11
Steroid hormones and glucocorticoids have been characterized as selective inhibitors of lymphopoiesis.
12
Additional studies, including a prospective trial of patients taking exogenous glucocorticoids, are warranted.
13
Seventeen cases were treated with glucocorticoids after the diagnosis was confirmed.
14
For several decades, glucocorticoids have been used empirically to treat rapid progressive GN.
15
The behavior of glucocorticoids during this period in these patients is not known.
16
Similarly, safety biomarkers may also be helpful assessing toxicity of alternatives to glucocorticoids.